ArticleJACC. Advances2026
Systemic Inflammation and Adverse Outcomes in Patients With Atherosclerotic Cardiovascular Disease and Chronic Kidney Disease.
Article in JACC. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSystemic inflammation (SI), measured by high-sensitivity C-reactive protein (hsCRP), is common in both atherosclerotic cardiovascular disease (ASCVD) and chronic kidney disease (CKD).
objectivesThe objectives of the study was to evaluate the association between SI and cardiovascular and economic outcomes among Veterans with ASCVD and CKD.
methodsWe conducted an analysis of Veterans with ASCVD and CKD with hsCRP testing between 2008 and 2022. We classified Veterans as with SI (hsCRP 2-10 mg/L) and without SI (hsCRP <2 mg/L). The primary outcome was the 3-point major adverse cardiovascular event (MACE) composite: death, myocardial infarction, and stroke. Additional outcomes included acute care utilization and health care costs. We evaluated the adjusted association between SI and clinical outcomes, acute care utilization, and costs via Cox regression, negative binomial regression, and gamma regression, respectively.
resultsVeterans with SI (n = 39,006) were younger (72.5 [SD: 9.1] vs 73.6 [SD: 9.1] years; P < 0.001) and had a higher prevalence of peripheral arterial disease (48.4% [18,860/39,006] vs 43.8% [10,152/23,176]; P < 0.001). Over a median follow-up of 4.2 years (IQR: 2.1-7.0; total of 307,074 person-years), the MACE rate was 11.64 (95% CI: 11.48-11.79) compared with 8.66 (95%CI: 8.49-8.83) per 100 patient-years in the group with vs without SI (P < 0.001). After adjustment, the HR for SI was 1.40 (95% CI: 1.36-1.43) for MACE. SI was significantly associated with increased hospitalizations (IRR: 1.24; 95% CI: 1.20-1.29) and $4,115 (95% CI: $1,878-$6,353) in additional costs over 1 year.
conclusionsAmong Veterans with ASCVD and CKD, SI was associated with an increased risk of MACE and higher health care utilization and costs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.